Fig. 4.
Fig. 4. Mutational analysis of the −164 and −177 PU.1 sites. Oligonucleotide probes were prepared in which the PU.1 sites at −164 and −177 were mutated (GAGGAA to GACTAA) either separately (P177M, lanes 4 through 6; and P164M, lanes 7 through 9) or in combination (P177/164M, lanes 10 through 12). Binding assays of nuclear extract (U) and in vitro-translated PU.1 (i.v. PU) to these probes were performed as described in the Materials and Methods and compared with binding to the unmutated wild-type oligonucleotide probe (−184/−150, lanes 1 through 3). Unlabeled double-stranded competitor oligonucleotides were added at 50-molar excess over the probe oligo (lanes 2, 5, 8, and 11). The arrow on the left indicates PU.1 binding to the oligonucleotide probes.

Mutational analysis of the −164 and −177 PU.1 sites. Oligonucleotide probes were prepared in which the PU.1 sites at −164 and −177 were mutated (GAGGAA to GACTAA) either separately (P177M, lanes 4 through 6; and P164M, lanes 7 through 9) or in combination (P177/164M, lanes 10 through 12). Binding assays of nuclear extract (U) and in vitro-translated PU.1 (i.v. PU) to these probes were performed as described in the Materials and Methods and compared with binding to the unmutated wild-type oligonucleotide probe (−184/−150, lanes 1 through 3). Unlabeled double-stranded competitor oligonucleotides were added at 50-molar excess over the probe oligo (lanes 2, 5, 8, and 11). The arrow on the left indicates PU.1 binding to the oligonucleotide probes.

Close Modal

or Create an Account

Close Modal
Close Modal